Chinese journal of cancer research = Chung-kuo yen cheng yen chiu最新文献

{"title":"Deep learning model improves radiologists' performance in detection and classification of breast lesions.","authors":"Yingshi Sun,&nbsp;Yuhong Qu,&nbsp;Dong Wang,&nbsp;Yi Li,&nbsp;Lin Ye,&nbsp;Jingbo Du,&nbsp;Bing Xu,&nbsp;Baoqing Li,&nbsp;Xiaoting Li,&nbsp;Kexin Zhang,&nbsp;Yanjie Shi,&nbsp;Ruijia Sun,&nbsp;Yichuan Wang,&nbsp;Rong Long,&nbsp;Dengbo Chen,&nbsp;Haijiao Li,&nbsp;Liwei Wang,&nbsp;Min Cao","doi":"10.21147/j.issn.1000-9604.2021.06.05","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2021.06.05","url":null,"abstract":"<p><strong>Objective: </strong>Computer-aided diagnosis using deep learning algorithms has been initially applied in the field of mammography, but there is no large-scale clinical application.</p><p><strong>Methods: </strong>This study proposed to develop and verify an artificial intelligence model based on mammography. Firstly, mammograms retrospectively collected from six centers were randomized to a training dataset and a validation dataset for establishing the model. Secondly, the model was tested by comparing 12 radiologists' performance with and without it. Finally, prospectively enrolled women with mammograms from six centers were diagnosed by radiologists with the model. The detection and diagnostic capabilities were evaluated using the free-response receiver operating characteristic (FROC) curve and ROC curve.</p><p><strong>Results: </strong>The sensitivity of model for detecting lesions after matching was 0.908 for false positive rate of 0.25 in unilateral images. The area under ROC curve (AUC) to distinguish the benign lesions from malignant lesions was 0.855 [95% confidence interval (95% CI): 0.830, 0.880]. The performance of 12 radiologists with the model was higher than that of radiologists alone (AUC: 0.852 <i>vs</i>. 0.805, P=0.005). The mean reading time of with the model was shorter than that of reading alone (80.18 s <i>vs</i>. 62.28 s, P=0.032). In prospective application, the sensitivity of detection reached 0.887 at false positive rate of 0.25; the AUC of radiologists with the model was 0.983 (95% CI: 0.978, 0.988), with sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of 94.36%, 98.07%, 87.76%, and 99.09%, respectively.</p><p><strong>Conclusions: </strong>The artificial intelligence model exhibits high accuracy for detecting and diagnosing breast lesions, improves diagnostic accuracy and saves time.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"33 6","pages":"682-693"},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/15/3d/cjcr-33-6-682.PMC8742176.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39596568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"All-trans retinoic acid (ATRA) inhibits insufficient radiofrequency ablation (IRFA)-induced enrichment of tumor-initiating cells in hepatocellular carcinoma.","authors":"Song Wang,&nbsp;Jingtao Liu,&nbsp;Hao Wu,&nbsp;Anna Jiang,&nbsp;Kun Zhao,&nbsp;Kun Yan,&nbsp;Wei Wu,&nbsp;Haibo Han,&nbsp;Yanhua Zhang,&nbsp;Wei Yang","doi":"10.21147/j.issn.1000-9604.2021.06.06","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2021.06.06","url":null,"abstract":"<p><strong>Objective: </strong>Local recurrence of hepatocellular carcinoma (HCC) after radiofrequency ablation (RFA) treatment remains a serious problem. Tumor-initiating cells (TICs) are thought to be responsible for tumor relapse. Here, we investigated the effect of the TIC differentiation inducer, all-trans retinoic acid (ATRA), on RFA and explored the potential molecular mechanisms.</p><p><strong>Methods: </strong>The proportions of CD133⁺ and epithelial cell adhesion molecule (EpCAM)⁺ TICs in recurrent HCC after RFA and primary HCC were first determined in clinic. Then, the effect of heat intervention or insufficient RFA (IRFA) on the malignant potential of HCC cells, including cell migration, sphere formation ability, tumor growth, the proportion of CD133⁺ and EpCAM⁺ TICs and expression of stem cell-related genes, was evaluated <i>in vitro</i> and<i>in vivo</i>. Finally, the effect of ATRA on the tumor growth and the proportion of TICs was evaluated.</p><p><strong>Results: </strong>In clinical data, a higher proportion of CD133⁺ and EpCAM⁺ TICs was found in recurrent tumors than in primary tumors. <i>In vitro</i> heat intervention promoted the cell migration and sphere formation ability. Additionally, it increased the proportion of CD133⁺ and EpCAM⁺ TICs and the expression of stem cell-related genes. In addition, after IRFA the residual tumors in xenografts grew faster and had more TICs than untreated tumors. ATRA remarkably inhibited residual tumor growth after IRFA by elimination of TICs though the PI3K/AKT pathway. Combination treatment with ATRA resulted in longer survival outcomes in mouse xenografts than RFA alone.</p><p><strong>Conclusions: </strong>ATRA, as a TIC differentiation inducer, could help to improve the effect of RFA treatment, which was partially attributed to its effect against TICs. The data indicated its potential as an alternative drug in the development of better therapeutic strategies for use in combination with RFA.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"33 6","pages":"694-707"},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/50/8c/cjcr-33-6-694.PMC8742172.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39596569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of centralization with health care quality for gastric cancer patients receiving gastrectomy in China.","authors":"Jiafu Ji,&nbsp;Leiyu Shi,&nbsp;Xiangji Ying,&nbsp;Xinpu Lu,&nbsp;Fei Shan,&nbsp;Haibo Wang","doi":"10.21147/j.issn.1000-9604.2021.06.03","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2021.06.03","url":null,"abstract":"<p><strong>Objective: </strong>Limited evidence is available regarding the associations of centralization with gastric cancer patients' quality of care in high surgical volume settings. The current study aimed to explore the effects of hospital volume and the Herfindahl-Hirschman index (HHI) on in-hospital mortality, total cost, and length of stay for Chinese gastrectomy patients in a nationwide database.</p><p><strong>Methods: </strong>We extracted data on gastrectomy for gastric cancer from the Hospital Quality Monitoring System Database between 2013 and 2018. Hospital volume was divided into 4 quartiles: low (1-83 cases per year), medium (84-238 cases), high (239-579 cases), and very high (580-1,193 cases). The HHI was divided into 3 categories: highly concentrated (>2,500), moderately concentrated (1,500-2,500), and unconcentrated (<1,500). We used mixed-effects models to analyze the data while accounting for data clustering.</p><p><strong>Results: </strong>We analyzed 125,683 patients in 515 institutions. In the multivariable analyses, hospital volume was significantly associated with in-hospital mortality [medium <i>vs.</i> low: odds ratio (OR)=0.61, 95% confidence interval (95% CI)=0.43-0.84, P=0.003; high: OR=0.57, 95% CI=0.38-0.87, P=0.009; and very high: OR=0.33, 95% CI=0.18-0.61, P<0.001) and length of stay (high<i>vs</i>. low: β=-0.036, 95% CI=-0.071--0.002, P=0.039) but not with total cost. Hospitals located in unconcentrated provinces had higher in-hospital mortality (OR=1.52, 95% CI=1.03-2.26, P=0.036) and longer lengths of stay (β=0.024, 95% CI=0.001-0.047, P=0.041) than hospitals located in highly concentrated provinces.</p><p><strong>Conclusions: </strong>Centralization of gastrectomy, measured by hospital volume and the HHI, was associated with decreased in-hospital mortality and shortened length of stay without increasing total cost. These results support the strategy of centralizing gastrectomy in high-volume settings.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"33 6","pages":"659-670"},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/3a/cjcr-33-6-659.PMC8742175.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39770201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of lymph node metastasis by computed tomography in early gastric cancer.","authors":"Jingtao Wei,&nbsp;Yinan Zhang,&nbsp;Zhilong Wang,&nbsp;Xiaojiang Wu,&nbsp;Ji Zhang,&nbsp;Zhaode Bu,&nbsp;Jiafu Ji","doi":"10.21147/j.issn.1000-9604.2021.06.04","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2021.06.04","url":null,"abstract":"<p><strong>Objective: </strong>Lymph node status is critical when selecting treatment methods for patients with early gastric cancer (EGC). The aim of this study was to assess the diagnostic value of computed tomography (CT) for detection of lymph node metastasis (LNM) in patients with EGC.</p><p><strong>Methods: </strong>We retrospectively analyzed patients who had pathologically confirmed EGC between November 2010 and January 2019. After 1:1 propensity score matching, 65 patients with LNM and 65 patients without LNM were retained for comparison. The long diameter (LD) and short diameter (SD) of all visualized lymph nodes in all stations were recorded. The diagnostic value of LNM was assessed with receiver operating characteristic analysis.</p><p><strong>Results: </strong>Among 130 patients, we found a total of 558 lymph nodes on the CT images. Among the diagnostic indicators, the number, sum of LD and sum of SD of lymph nodes greater than 3 mm had better discrimination. The areas under the curve were all greater than 0.75. As for different regions, the optimal cutoff values of number, the sum of LD and sum of SD were determined as follows: overall, ≥4, 19.9 mm and 13.5 mm; left gastric artery basin, ≥3, 15.7 mm and 8.6 mm; right gastroepiploic artery basin, ≥2, 8.6 mm and 7.0 mm.</p><p><strong>Conclusions: </strong>CT is valuable for diagnosing LNM in EGC patients. The number, sum of LD and sum of SD of lymph nodes greater than 3 mm are preferable indicators. Different regional lymph nodes have different optimal criteria for predicting LNM in ECG patients.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"33 6","pages":"671-681"},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f2/a4/cjcr-33-6-671.PMC8742171.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39770202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Novel technologies in cfDNA analysis and potential utility in clinic.","authors":"Jie Li,&nbsp;Mengyue Xu,&nbsp;Junya Peng,&nbsp;Jingqiao Wang,&nbsp;Yupei Zhao,&nbsp;Wenming Wu,&nbsp;Xun Lan","doi":"10.21147/j.issn.1000-9604.2021.06.07","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2021.06.07","url":null,"abstract":"<p><p>The profiling of plasma cell-free DNA (cfDNA) is becoming a valuable tool rapidly for tumor diagnosis, monitoring and prognosis. Diverse plasma cfDNA technologies have been in routine or emerging use, including analyses of mutations, copy number alterations, gene fusions and DNA methylation. Recently, new technologies in cfDNA analysis have been developed in laboratories, and potentially reflect the status of epigenetic modification, the immune microenvironment and the microbiome in tumor tissues. In this review, the authors discuss the principles, methods and effects of the current cfDNA assays and provide an overview of studies that may inform clinical applications in the near future.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"33 6","pages":"708-718"},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fe/79/cjcr-33-6-708.PMC8742177.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39596574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prudent application of single-cell RNA sequencing in understanding cellular features and functional phenotypes in cancer studies.","authors":"Xuanhao Xu,&nbsp;Zemin Zhang","doi":"10.21147/j.issn.1000-9604.2021.06.08","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2021.06.08","url":null,"abstract":"<p><p>This decade has seen remarkable advances in the field of high-throughput single cell techniques. Single-cell RNA sequencing (scRNA-seq) has proven to be a powerful strategy to study the heterogeneity in clinical samples, providing an unbiased approach to uncover the characteristics in different cell subsets. To ensure the reproducibility and robustness of biological discoveries, researchers need to be aware of hidden caveats in tissue dissociation, cell capturing and transcripts measurement which may affect cell composition assessment and cellular function annotation. With measured interpretation of data and innovations in experimental and technical approaches, scRNA-seq can greatly unravel the heterogeneity in complex system and improve our understandings in tissue homeostasis and cancer biology.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"33 6","pages":"719-723"},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bb/62/cjcr-33-6-719.PMC8742178.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39596572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"ZNF292 suppresses proliferation of ESCC cells through ZNF292/SKP2/P27 signaling axis.","authors":"Wei Gong,&nbsp;Jiancheng Xu,&nbsp;Guangchao Wang,&nbsp;Dan Li,&nbsp;Qimin Zhan","doi":"10.21147/j.issn.1000-9604.2021.06.01","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2021.06.01","url":null,"abstract":"<p><strong>Objective: </strong>Increasing evidence has demonstrated that ZNF292 plays a suppressive role in cancer, however, little is known about its function and exact mechanism in esophageal squamous cell carcinoma (ESCC).</p><p><strong>Methods: </strong>Bioinformatic analysis and immunohistochemistry (IHC) were performed to analyze the role of ZNF292 in affecting the prognosis of ESCC. Cell proliferation and colony formation ability assays were performed to analyze cell growth after inferring the expression of ZNF292. Flow cytometry was used to analyze changes in the cell cycle upon the depletion of ZNF292. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blot analysis were used to determine the alteration of cell cycle related RNAs and proteins after knocking down ZNF292. MG-132, cycloheximide (CHX) treatment experiments were performed to analyze the change and half-life time of P27 after knockdown of ZNF292. Chromatin immunoprecipitation (ChIP) and luciferase reporter assays were used to analyze the transcriptional regulation of SKP2 by ZNF292.</p><p><strong>Results: </strong>We report that low expression of ZNF292 is associated with poor prognosis, and ZNF292 emerges to be highly expressed in adjacent and normal tissues rather than tumor tissues in ESCC. Knockdown of ZNF292 significantly boosts cell growth and S phase entry in ESCC cells. ZNF292 depletion will decrease the expression and half-life time of P27, while knockdown of SKP2 will result in elevated expression of P27. ZNF292 can bind to the promoter region of SKP2, and knockdown of ZNF292 will boost the expression of SKP2.</p><p><strong>Conclusions: </strong>Knockdown of ZNF292 mediates G1/S cell cycle procession by activating SKP2/P27 signaling in ESCC cells. ZNF292 knockdown promotes SKP2 expression at the transcriptional level, thereby boosting P27 ubiquitin-degradation, and eventually facilitating the S phase entrance.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"33 6","pages":"637-648"},"PeriodicalIF":0.0,"publicationDate":"2021-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/bf/5e/cjcr-33-6-637.PMC8742179.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39770198","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Coexisting opportunities and challenges: In which scenarios can minimal/measurable residual disease play a role in advanced non-small cell lung cancer?","authors":"Hanfei Guo,&nbsp;Wenqian Li,&nbsp;Bin Wang,&nbsp;Neifei Chen,&nbsp;Lei Qian,&nbsp;Jiuwei Cui","doi":"10.21147/j.issn.1000-9604.2021.05.04","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2021.05.04","url":null,"abstract":"<p><p>Curative therapy was not previously available for patients with advanced non-small cell lung cancer (NSCLC); thus, the concept of minimal/measurable (or molecular) residual disease (MRD) was not applicable to these patients. However, advances in targeted and immunotherapy have revolutionized the treatment landscape for patients with advanced NSCLC, with emerging evidence of long-term survival and even the hope of complete remission (CR) by imaging examination. The latest research shows that patients with oligometastatic lung cancer can benefit from local treatment. After removing the lesions, the choice of follow-up therapy and monitoring of the lesions could remain uncertain. MRD plays a role in identifying early-stage NSCLC patients with high risks of recurrence and determining adjuvant therapy after radical treatment. In recent years, evidence has been accumulating regarding the use of circulating cell-free tumor DNA (ctDNA) to assess MRD in solid tumors. This study discussed the possible applications of ctDNA-based MRD monitoring in advanced NSCLC and described the current challenges and unresolved problems in the application of MRD in advanced NSCLC.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"33 5","pages":"574-582"},"PeriodicalIF":0.0,"publicationDate":"2021-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c1/22/cjcr-33-5-574.PMC8580798.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39741677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma.","authors":"Lin Gui,&nbsp;Junning Cao,&nbsp;Dongmei Ji,&nbsp;Huilai Zhang,&nbsp;Qian Fan,&nbsp;Jun Zhu,&nbsp;Yuqin Song,&nbsp;Shiyu Jiang,&nbsp;Zhiqiang Ning,&nbsp;Jia Yu,&nbsp;Yuankai Shi","doi":"10.21147/j.issn.1000-9604.2021.05.08","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2021.05.08","url":null,"abstract":"<p><strong>Objective: </strong>Chidamide is an oral histone deacetylase subtype-selective inhibitor approved for relapsed or refractory peripheral T-cell lymphoma (PTCL). This phase 1b study evaluated the safety, pharmacokinetics, and preliminary efficacy of chidamide in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for treatment-naïve PTCL patients.</p><p><strong>Methods: </strong>This study was an open-label, multicenter trial composed of dose escalation and dose expansion. Patients received CHOP for six 21-d cycles and chidamide on d 1, 4, 8 and 11 in each cycle. Four dose levels of chidamide (20, 25, 30 and 35 mg) were evaluated. The primary objective was to evaluate the safety and tolerability of the combination regimen.</p><p><strong>Results: </strong>A total of 30 patients were evaluated in this study: 15 in the dose-escalation part and 15 in the dose-expansion part. In the dose-escalation study, three patients were enrolled in the 35 mg chidamide cohort. One had dose-limiting toxicity with grade 3 vascular access complications, and one had grade 2 neutropenia with a sustained temperature >38 °C. Dose escalation was stopped at this chidamide dose level. The most common (≥10%) grade 3 or 4 adverse events (AEs) were leukopenia (90.0%), neutropenia (83.3%), vomiting (13.3%), thrombocytopenia (10.0%) and febrile neutropenia (10.0%). No significant changes in chidamide pharmacokinetic properties were observed before and after combination treatment. The objective response rate for the 28 patients evaluable for preliminary efficacy was 89.3% (25/28), with 16 (57.1%) achieving complete response or unconfirmed complete response. The estimated median progression-free survival was 14.0 months. In summary, we chose chidamide 30 mg as the recommended dose for phase 2.</p><p><strong>Conclusions: </strong>The addition of chidamide to standard CHOP chemotherapy was tolerable with promising preliminary efficacy in previously untreated PTCL patients, which supports further clinical studies with this combination regimen for the frontline treatment of PTCL.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"33 5","pages":"616-626"},"PeriodicalIF":0.0,"publicationDate":"2021-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cf/00/cjcr-33-5-616.PMC8580795.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39652740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung cancer risk in never-smokers: An overview of environmental and genetic factors.","authors":"Elvin S Cheng,&nbsp;Marianne Weber,&nbsp;Julia Steinberg,&nbsp;Xue Qin Yu","doi":"10.21147/j.issn.1000-9604.2021.05.02","DOIUrl":"https://doi.org/10.21147/j.issn.1000-9604.2021.05.02","url":null,"abstract":"<p><p>Lung cancer is the leading cause of cancer-related mortality globally, accounting for 1.8 million deaths in 2020. While the vast majority are caused by tobacco smoking, 15%-25% of all lung cancer cases occur in lifelong never-smokers. The International Agency for Research on Cancer (IARC) has classified multiple agents with sufficient evidence for lung carcinogenesis in humans, which include tobacco smoking, as well as several environmental exposures such as radon, second-hand tobacco smoke, outdoor air pollution, household combustion of coal and several occupational hazards. However, the IARC evaluation had not been stratified based on smoking status, and notably lung cancer in never-smokers (LCINS) has different epidemiological, clinicopathologic and molecular characteristics from lung cancer in ever-smokers. Among several risk factors proposed for the development of LCINS, environmental factors have the most available evidence for their association with LCINS and their roles cannot be overemphasized. Additionally, while initial genetic studies largely focused on lung cancer as a whole, recent studies have also identified genetic risk factors for LCINS. This article presents an overview of several environmental factors associated with LCINS, and some of the emerging evidence for genetic factors associated with LCINS. An increased understanding of the risk factors associated with LCINS not only helps to evaluate a never-smoker's personal risk for lung cancer, but also has important public health implications for the prevention and early detection of the disease. Conclusive evidence on causal associations could inform longer-term policy reform in a range of areas including occupational health and safety, urban design, energy use and particle emissions, and the importance of considering the impacts of second-hand smoke in tobacco control policy.</p>","PeriodicalId":9830,"journal":{"name":"Chinese journal of cancer research = Chung-kuo yen cheng yen chiu","volume":"33 5","pages":"548-562"},"PeriodicalIF":0.0,"publicationDate":"2021-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/a3/cjcr-33-5-548.PMC8580800.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39741676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}